The 60-second version of Anlon Healthcare Limited — what it does, how it earns, and who it competes with, before any of the numbers below.
| Metric | FY23 | FY24 | FY25 | FY26 | 3Y CAGR |
|---|---|---|---|---|---|
| Revenue | ₹113 Cr | ₹67 Cr | ₹120 Cr | ₹172 Cr | +15.1% |
| EBITDA | ₹13 Cr | ₹16 Cr | ₹32 Cr | ₹47 Cr | +54.6% |
| EBITDA Margin | 11.2% | 23.6% | 26.7% | 27.2% | — |
| PAT (Net Profit) | ₹6 Cr | ₹10 Cr | ₹21 Cr | ₹29 Cr | +69.8% |
| EPS | ₹0.11 | ₹0.18 | ₹0.39 | ₹0.6 | +76.2% |
| ROE | 78.9% | 45.9% | 25.5% | 12.4% | — |
| ROCE | 15.9% | 17.8% | 25.0% | 17.0% | — |
| Total Debt | ₹70 Cr | ₹81 Cr | ₹67 Cr | ₹44 Cr | -14.7% |
| Free Cash Flow | -₹3 Cr | -₹7 Cr | -₹23 Cr | -₹116 Cr | — |
| Company | P/E | ROE |
|---|---|---|
| SUN PHARMACEUTICAL IND L | 34.9x | 14.5% |
| DR. REDDY S LABORATORIES | 31.0x | 8.8% |
| CIPLA LTD | 31.8x | 9.8% |
| DIVI S LABORATORIES LTD | 83.0x | 17.5% |
A sound business at a reasonable valuation. Suitable for a long-term holding, with the valuation and the direction of margins worth watching rather than the business itself. 4 high-severity red flags sit above this conclusion and should be read first.